UNITY Biotechnologies selects a new Senolytic Candidate
Unity Biotechnologies has begun the development of another senolytic candidate. Senolytics are used to rid the body of harmful cells that accumulate as we age. These cells can lead to age-related illnesses.
New treatment for age-related eye diseases
UNITY Biotechnologies recently announced that it had selected UBX1967 as a lead drug to treat a variety of age-related eye diseases. This $677 million company has a second drug in its pipeline. This drug is unique among eye treatments; it targets senescent and destroys them, making it a Senolytic. It targets the disease by targeting one of the causes of aging.
Source:
https://www.leafscience.org/unity-biotechnologies-selects-a-new-senolytic-candidate/
